Comparing 2 biotech companies’ business models and the way they get financed: Funding rounds vs. collaboration with pharma

Edition

Comparing 2 biotech companies’ business models and the way they get financed: Funding rounds vs. collaboration with pharma

What are the alternatives to the prevailing model of fundraising? Are there concrete growth opportunities relying only on licensing and collaboration deals? What are the criteria for fulfilling this alternative route? This session will draw on the experience of biotech companies embodying these different models.

Naheed Kurji

Co-founder, President & CEO
Canada
Cyclica

Natalia Novac

Senior Director Venture Science, Corporate Business Development
United Kingdom
Eli Lilly and Company

Laurent Nguyen

Co-Founder & CEO
Spain
Accure Therapeutics

Sonia Hallen

Associate
The Netherlands
LSP

Claire Skentelbery

Director General
Belgium
EuropaBio
  • No products in the cart.